Sanford C. Bernstein Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $82.00

Key Points

• Sanford C. Bernstein cut its price target on BioMarin from $94 to $82 but kept an "outperform" rating, implying roughly a 53% upside from the recent close.
• BioMarin reported a mixed Q1 — revenue beat and raised full‑year revenue guidance ($3.825B–$3.925B), but Q1 EPS of $0.76 missed estimates and FY EPS guidance of $4.85–$5.05 was modestly below Street, and the stock fell to $53.57 (down ~3.4%).
• The sell‑side is mixed but generally positive: MarketBeat shows a consensus of "Moderate Buy" with an average target of $90.32, even as several major firms recently trimmed price targets and insiders have reduced positions amid ~98.7% institutional ownership.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its target price reduced by Sanford C. Bernstein from $94.00 to $82.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. Sanford C. Bernstein's target price indicates a potential upside of 53.08% from the company's previous close.

Other research analysts also recently issued research reports about the company. Jefferies Financial Group reissued a "buy" rating and issued a $103.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, March 12th. Weiss Ratings raised BioMarin Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday. Piper Sandler lowered their target price on BioMarin Pharmaceutical from $122.00 to $84.00 and set an "overweight" rating on the stock in a report on Friday, February 6th. Guggenheim cut their price objective on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. Finally, Morgan Stanley cut their price objective on shares of BioMarin Pharmaceutical from $120.00 to $119.00 and set an "overweight" rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $90.32.

BioMarin Pharmaceutical Stock Down 3.4%

Shares of BMRN traded down $1.89 on Tuesday, hitting $53.57. 1,582,539 shares of the stock traded hands, compared to its average volume of 2,007,297. The company has a market capitalization of $10.35 billion, a PE ratio of 30.16, a P/E/G ratio of 0.54 and a beta of 0.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21. The business has a 50 day simple moving average of $56.93 and a 200 day simple moving average of $56.32. BioMarin Pharmaceutical has a one year low of $50.76 and a one year high of $66.28.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Gregory R. Friberg sold 6,326 shares of the company's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the transaction, the executive vice president owned 37,578 shares of the company's stock, valued at approximately $2,268,959.64. This represents a 14.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Charles Greg Guyer sold 16,486 shares of the company's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares of the company's stock, valued at $4,833,958.38. This represents a 17.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.85% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Viking Global Investors LP boosted its holdings in BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock worth $675,505,000 after buying an additional 1,488,552 shares during the period. Norges Bank bought a new position in BioMarin Pharmaceutical in the 4th quarter worth $447,572,000. AQR Capital Management LLC boosted its holdings in BioMarin Pharmaceutical by 12.7% in the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company's stock worth $395,197,000 after buying an additional 754,807 shares during the period. Geode Capital Management LLC boosted its holdings in BioMarin Pharmaceutical by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 3,674,089 shares of the biotechnology company's stock worth $218,395,000 after buying an additional 131,969 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in BioMarin Pharmaceutical by 48.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company's stock worth $197,405,000 after purchasing an additional 1,076,568 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q1 revenue beat estimates and company raised full‑year revenue guidance to $3.825B–$3.925B, citing portfolio additions (GALAFOLD®, POMBILITI® + OPFOLDA®) as growth drivers — this supports longer‑term top‑line growth expectations. PR Newswire: BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Royal Bank of Canada reaffirmed its "sector perform" rating and set a $66 price target (~21% upside from current levels), which could provide analyst‑driven support if sentiment improves. TickerReport / Benzinga: RBC reaffirms rating, $66 PT
• Neutral Sentiment: HC Wainwright reaffirmed a "neutral" rating with a $55 price target — little change to sell‑side consensus and a reminder of mixed analyst views. TickerReport / Benzinga: HC Wainwright reaffirmation
• Neutral Sentiment: Full Q1 earnings call transcript and slide deck are available for details on drivers and margin outlook; these materials may clarify management's path to margin improvement. Seeking Alpha: Q1 2026 earnings call transcript
• Negative Sentiment: Q1 EPS of $0.76 missed the Zacks consensus of $0.94 and fell year‑over‑year, a clear near‑term earnings disappointment that weighs on valuation multiples. Zacks: Q1 earnings lag estimates
• Negative Sentiment: FY EPS guidance was set at $4.85–$5.05 vs. a Street consensus near $4.98 — a mild shortfall that, combined with the EPS miss, increases near‑term investor caution despite revenue upside. BioMarin Q1 press materials (slide deck / press release)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.